What are IPF and ILD?

Idiopathic pulmonary fibrosis (IPF) is a type of interstitial lung disease (ILD), a group of diseases marked by diffuse scarring in the lung tissue. There are many causes of ILDs, including environmental exposures, autoimmune (rheumatologic) conditions, genetic and other factors. In contrast, the cause of IPF is not well understood but thought related at least in part to genetic factors. More research is needed to understand the specific factors that lead to the development of IPF and ILDs.

How are they treated?

IPF and other ILDs often progress over time, and there is currently no cure for IPF. Current treatments to slow disease progression and help improve quality of life include medicines, oxygen therapy, and pulmonary rehabilitation. Lung transplantation may be an option for selected patients with very advanced disease.

Why is more research needed?

Although relatively rare, IPF and other ILDs are increasingly recognized. To better understand these diseases, the IPF-PRO/ILD-PRO Registry has enrolled more than 2,000 people and provides comprehensive data and insights into various ILDs. Findings from ongoing clinical research—including the Registry—can help clinicians find ways to better support people with IPF and ILD to treat and manage these diseases.